Ubs Asset Management Americas Inc Crinetics Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 325,276 shares of CRNX stock, worth $9.69 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
325,276
Previous 271,747
19.7%
Holding current value
$9.69 Million
Previous $13.9 Million
19.82%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding CRNX
# of Institutions
256Shares Held
82.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$271 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$186 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$183 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$161 Million0.03% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.29MShares$128 Million10.24% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.6B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...